

Wenxin Zheng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4446962/publications.pdf>

Version: 2024-02-01

64
papers

1,260
citations

471477

17
h-index

395678

33
g-index

69
all docs

69
docs citations

69
times ranked

1757
citing authors

#	ARTICLE	IF	CITATIONS
1	Tubal origin of ovarian low-grade serous carcinoma. <i>Modern Pathology</i> , 2011, 24, 1488-1499.	5.5	136
2	Endometrial Glandular Dysplasia with Frequent p53 Gene Mutation: A Genetic Evidence Supporting Its Precancer Nature for Endometrial Serous Carcinoma. <i>Clinical Cancer Research</i> , 2008, 14, 2263-2269.	7.0	111
3	A Proposed Model for Endometrial Serous Carcinogenesis. <i>American Journal of Surgical Pathology</i> , 2011, 35, e1-e14.	3.7	97
4	Frequent Expression of Napsin A in Clear Cell Carcinoma of the Endometrium. <i>American Journal of Surgical Pathology</i> , 2014, 38, 189-196.	3.7	88
5	The clinicopathologic significance of p53 and BAF-250a (ARID1A) expression in clear cell carcinoma of the endometrium. <i>Modern Pathology</i> , 2013, 26, 1101-1110.	5.5	81
6	De novo prediction of cancer-associated T cell receptors for noninvasive cancer detection. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	59
7	Metformin sensitizes endometrial cancer cells to chemotherapy through IDH1-induced Nrf2 expression via an epigenetic mechanism. <i>Oncogene</i> , 2018, 37, 5666-5681.	5.9	56
8	Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-AKR1C1 pathway. <i>Oncotarget</i> , 2016, 7, 10363-10372.	1.8	47
9	Estrogen affects the negative feedback loop of PTEN1-miR200c to inhibit PTEN expression in the development of endometrioid endometrial carcinoma. <i>Cell Death and Disease</i> , 2019, 10, 4.	6.3	36
10	PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma. <i>American Journal of Surgical Pathology</i> , 2020, 44, 1050-1060.	3.7	34
11	Utility of Î±-methylacyl-coenzyme-A racemase (p504s) immunohistochemistry in distinguishing endometrial clear cell carcinomas from serous and endometrioid carcinomas. <i>Human Pathology</i> , 2013, 44, 2814-2821.	2.0	32
12	Primary sources of pelvic serous cancer in patients with endometrial intraepithelial carcinoma. <i>Modern Pathology</i> , 2015, 28, 118-127.	5.5	29
13	Tubal origin of ovarian endometriosis. <i>Modern Pathology</i> , 2014, 27, 1154-1162.	5.5	28
14	Expression of the oncofetal protein IGF2BP3 in endometrial clear cell carcinoma: assessment of frequency and significance. <i>Human Pathology</i> , 2013, 44, 1508-1515.	2.0	24
15	Targeted Molecular and Immunohistochemical Analyses of Endometrial Clear Cell Carcinoma Show that POLE Mutations and DNA Mismatch Repair Protein Deficiencies Are Uncommon. <i>American Journal of Surgical Pathology</i> , 2019, 43, 531-537.	3.7	24
16	Stigmasterol sensitizes endometrial cancer cells to chemotherapy by repressing Nrf2 signal pathway. <i>Cancer Cell International</i> , 2020, 20, 480.	4.1	20
17	Assessment of the Utility of PAX8 Immunohistochemical Stain in Diagnosing Endocervical Glandular Lesions. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 148-152.	2.5	19
18	Association between human papillomavirus type 16 E6 and E7 variants with subsequent persistent infection and recurrence of cervical high-grade squamous intraepithelial lesion after conization. <i>Journal of Medical Virology</i> , 2016, 88, 1982-1988.	5.0	18

#	ARTICLE	IF	CITATIONS
19	Metformin sensitizes endometrial cancer cells to progestin by targeting TET1 to downregulate glyoxalase I expression. <i>Biomedicine and Pharmacotherapy</i> , 2019, 113, 108712.	5.6	18
20	Gene expression profiles of ovarian low-grade serous carcinoma resemble those of fallopian tube epithelium. <i>Gynecologic Oncology</i> , 2017, 147, 634-641.	1.4	15
21	Variants of human papillomavirus type 16 predispose toward persistent infection. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 8453-9.	0.5	15
22	Cytologic studies of the fallopian tube in patients undergoing salpingo-oophorectomy. <i>Cancer Cell International</i> , 2016, 16, 78.	4.1	14
23	Does a p53 "Wild-type" Immunophenotype Exclude a Diagnosis of Endometrial Serous Carcinoma?. <i>Advances in Anatomic Pathology</i> , 2018, 25, 61-70.	4.3	13
24	Are clear cell carcinomas of the ovary and endometrium phenotypically identical? A proteomic analysis. <i>Human Pathology</i> , 2015, 46, 1427-1436.	2.0	12
25	Tubal origin of ovarian endometriosis and clear cell and endometrioid carcinoma. <i>American Journal of Cancer Research</i> , 2015, 5, 869-79.	1.4	12
26	Fallopian tube secretory cell expansion: a sensitive biomarker for ovarian serous carcinogenesis. <i>American Journal of Translational Research (discontinued)</i> , 2015, 7, 2082-90.	0.0	12
27	Flutamide and Biomarkers in Women at High Risk for Ovarian Cancer: Preclinical and Clinical Evidence. <i>Cancer Prevention Research</i> , 2014, 7, 896-905.	1.5	11
28	Overexpression and oncogenic function of HMGA2 in endometrial serous carcinogenesis. <i>American Journal of Cancer Research</i> , 2016, 6, 249-59.	1.4	11
29	Prevalence and prognostic significance of PD-L1, TIM-3 and B7-H3 expression in endometrial serous carcinoma. <i>Modern Pathology</i> , 2022, 35, 1955-1965.	5.5	11
30	Pathological findings in explanted vaginal mesh. <i>Human Pathology</i> , 2017, 69, 46-54.	2.0	10
31	Tubal Origin of "Ovarian" Low-Grade Serous Carcinoma: A Gene Expression Profile Study. <i>Journal of Oncology</i> , 2019, 2019, 1-9.	1.3	10
32	Challenges in the Pap diagnosis of endocervical adenocarcinoma in situ. <i>Journal of the American Society of Cytopathology</i> , 2019, 8, 141-148.	0.5	9
33	Serial genomic analysis of endometrium supports the existence of histologically indistinct endometrial cancer precursors. <i>Journal of Pathology</i> , 2021, 254, 20-30.	4.5	9
34	High-grade endometrial carcinomas: Morphologic spectrum and molecular classification. <i>Seminars in Diagnostic Pathology</i> , 2022, 39, 176-186.	1.5	9
35	PD-L1 Expression in Endometrial Serous Carcinoma and Its Prognostic Significance. <i>Cancer Management and Research</i> , 2021, Volume 13, 9157-9165.	1.9	9
36	Ovarian serous carcinogenesis from tubal secretory cells. <i>Histology and Histopathology</i> , 2015, 30, 1295-302.	0.7	9

#	ARTICLE	IF	CITATIONS
37	Classifying Anal Intraepithelial Neoplasia 2 Based on LAST Recommendations. American Journal of Clinical Pathology, 2021, 155, 845-852.	0.7	8
38	Endometrial stromal tumors: Diagnostic updates and challenges. Seminars in Diagnostic Pathology, 2022, 39, 201-212.	1.5	8
39	Endometrial polyps are non-neoplastic but harbor epithelial mutations in endometrial cancer drivers at low allelic frequencies. Modern Pathology, 2022, 35, 1702-1712.	5.5	8
40	Tubal Cytology of the Fallopian Tube as a Promising Tool for Ovarian Cancer Early Detection. Journal of Visualized Experiments, 2017, , .	0.3	7
41	Biomarkers and endosalpingiosis in the ovarian and tubal microenvironment of women at high-risk for pelvic serous carcinoma. American Journal of Cancer Research, 2014, 4, 61-72.	1.4	7
42	Effect of luteinizing hormone-induced prohibitin and matrix metalloproteinases on ovarian epithelial tumor cell proliferation. American Journal of Cancer Research, 2015, 5, 114-24.	1.4	7
43	Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-survivin pathway. American Journal of Translational Research (discontinued), 2017, 9, 1483-1491.	0.0	7
44	The IVF-generated human embryonic microenvironment reverses progestin resistance in endometrial cancer cells by inducing cancer stem cell differentiation. Cancer Letters, 2022, 526, 311-321.	7.2	7
45	Negative Predictive Value of Human Papillomavirus Testing: Implications for Anal Cancer Screening in People Living with HIV/AIDS. Journal of Oncology, 2020, 2020, 1-7.	1.3	6
46	The significance of L1^{CAM} expression in clear cell carcinoma of the endometrium. Histopathology, 2018, 72, 532-538.	2.9	5
47	Superficially invasive cervical squamous cell carcinoma metastatic to ovarian endometriotic cyst wall, a case report and brief review of the literature. Journal of Ovarian Research, 2018, 11, 44.	3.0	4
48	Age cutoff for reporting of benign-appearing endometrial cells in Papanicolaou specimens; should it be raised? A 10-year retrospective study from a large county hospital. Journal of the American Society of Cytopathology, 2019, 8, 78-83.	0.5	4
49	p16 Immunoreactivity Correlates With Morphologic Diagnosis of HPV-associated Anal Intraepithelial Neoplasia. American Journal of Surgical Pathology, 2021, 45, 1573-1578.	3.7	4
50	The Prognostic Values of HPV Genotypes and Tumor PD-L1 Expression in Patients With HPV-associated Endocervical Adenocarcinoma. American Journal of Surgical Pathology, 2022, 46, 300-308.	3.7	4
51	Navigating through perplex morphologic changes after exogenous hormone usage. Seminars in Diagnostic Pathology, 2022, 39, 148-158.	1.5	4
52	Combination of TP53 and AGR3 to distinguish ovarian high-grade serous carcinoma from low-grade serous carcinoma. International Journal of Oncology, 2018, 52, 2041-2050.	3.3	3
53	HIV-Infected Patients With Anal Cancer Precursors: Clinicopathological Characteristics and Human Papillomavirus Subtype Distribution. Diseases of the Colon and Rectum, 2020, 63, 890-896.	1.3	3
54	HPV Genotype Specific and Age Stratified Immediate Prevalence of Cervical Precancers and Cancers in Women with NILM/hrHPV+: A Single Center Retrospective Study of 26,228 Cases. Cancer Management and Research, 2021, Volume 13, 6869-6877.	1.9	3

#	ARTICLE	IF	CITATIONS
55	Tubal origin of ovarian low-grade serous carcinoma. American Journal of Clinical and Experimental Obstetrics and Gynecology, 2013, 1, 13-36.	0.5	3
56	BRCA1 expression, proliferative and apoptotic activities in ovarian epithelial inclusions. Journal of Ovarian Research, 2017, 10, 12.	3.0	2
57	Concurrent, Bilateral Presentation of Immature and Mature Ovarian Teratomas with Refractory Hyponatremia: A Case Report. Journal of Clinical Imaging Science, 2020, 10, 23.	1.1	2
58	Endocervical neoplasia: Pathologic updates in diagnosis and prognosis. Seminars in Diagnostic Pathology, 2021, , .	1.5	2
59	<p>Dedifferentiated Endometrioid Carcinomas with Neuroendocrine Differentiation: A Clinicopathological and Immunohistochemical Study of Three Cases</p>. Cancer Management and Research, 2020, Volume 12, 11623-11629.	1.9	1
60	HIV-positive women with anal high-grade squamous intraepithelial lesions: a study of 153 cases with long-term anogenital surveillance. Modern Pathology, 2020, 33, 1589-1594.	5.5	1
61	Lynch Syndrome Identification in Endometrial Cancer Patients: Should Universal Screening be Used for all Histologies?. Current Women's Health Reviews, 2021, 17, .	0.2	0
62	Precancerous lesions and an emerging model of endometrial serous carcinogenesis: clinical implications. Expert Review of Obstetrics and Gynecology, 2012, 7, 297-299.	0.4	0
63	Significance of degree of destructive stromal invasion in early stage endocervical adenocarcinoma.. Journal of Clinical Oncology, 2019, 37, e17023-e17023.	1.6	0
64	Fallopian tube secretory cell expansion: a sensitive biomarker for ovarian serous carcinogenesis. American Journal of Translational Research (discontinued), 2016, 8, 230-8.	0.0	0